Efficacy and Safety Study of Moxidectin in Adults With Scabies

NCT05875441 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2025-05-04

No results posted yet for this study

Summary

Moxidectin is not approved to treat scabies in humans. The effective dose of moxidectin to treat scabies is not known. This study aims to assess the efficacy of a single administration of 8 mg, 16 mg, or 32 mg moxidectin per oral in achieving Scabies Complete Cure at Day 28. This study also aims to assess the safety of three strengths of single moxidectin doses in adults with scabies.

Conditions

  • Scabies

Interventions

DRUG

Moxidectin Oral Product

The required number of moxidectin 2 mg tablet over encapsulated capsules will be administered as a single dose with placebo capsules to match as required

DRUG

Moxidectin Oral Product

The required number of moxidectin 2 mg tablet over encapsulated capsules will be administered as a single dose with placebo capsules to match as required

DRUG

Moxidectin Oral Product

The required number of moxidectin 2 mg tablet over encapsulated capsules will be administered as a single dose.

DRUG

Placebo

16 placebo capsules will be administered as a single dose.

Sponsors & Collaborators

  • Medicines Development for Global Health

    lead OTHER

Principal Investigators

  • Richard L Fernandez, MD · Advance Care and Clinical Trials

  • Jorge Lopez, MD · Hospital y Clinica Bendana

  • Daisy Blanco, MD · Instituto Dermatologico Dominicano y Cirugia de Pie

  • Jorge Castillo Molina, MD · Affinity Clinical Research Services

  • Patricia A Zuniga Munoz, MD · Derclinic

  • Laura B Vargas Rivas, MD · Vargas Clinic

  • Gilberto Perez, MD · Evolution Clinical Trials

  • Armando Pineda-Velez, MD · Medical Research of Westchester, Inc

  • Bruce Torkan, MD · LA Universal Research Center, Inc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-23
Primary Completion
2024-11-27
Completion
2025-02-11
FDA Drug
Yes

Countries

  • United States
  • Dominican Republic
  • El Salvador
  • Honduras

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05875441 on ClinicalTrials.gov